University of Toledo

Institutional Biosafety Committee

Date: December 18, 2025

Meeting time: 12.00 pm- 2.00 pm

Meeting type: Hybrid (Microsoft Teams and HEB 233)

Attendees/Roster:

Member	Attended	Voting	Scientific	Affiliated
DeLaSerna, Ivana	No	Yes	Yes	Yes
Dinardo, Robert S	Yes	Yes	Yes	No
Dudley, Richard	No	Yes	Yes	No
Gray, John	No	Yes	Yes	Yes
Kalinoski, Andrea L.	Yes	Yes	Yes	Yes
Leisner, Scott M.	Yes	Yes	Yes	Yes
Peseckis, Steven M.	Yes	Yes	Yes	Yes
Pillai, Mahesh R	Yes	Yes	Yes	Yes
Rohrs, Skylar Lee	Yes	Yes	Yes	Yes
Root, Lisa Jane	Yes	Yes	Yes	Yes
Shemshedini, Lirim	No	Yes	Yes	Yes
Shupp, Andrew Charles (Alt)	No	No	Yes	Yes
Taylor, Roger Travis	Yes	Yes	Yes	Yes
Wooten, Ronald Mark	Yes	Yes	Yes	Yes
Guests: None				
IBC staff: Dissanayake, Ravindika				

Quorum: Present

There were (9) voting members present, and (7) members are required to conduct business.

Call to Order: The IBC Chair called the meeting to order at 12.08 pm

Review and approval of previous minutes:

Date of the meeting minutes to be approved. November 20, 2025

- **Discussion**: None
- **Motion**: The committee approved the unredacted updated November meeting minutes as written.
- **Votes**: For/Against/Abstain: 9/0/0

Review of Prior Business/Biosafety officers report:

- Mr. Rohrs mentioned [redacted]

Protocol Review

IBC # 500189 -New Submission	**P.I.:** Dr. Tao Yang	**Training:** IBC Laboratory Safety Training	**Biosafety Level Assignment:** BSL-2
Title: Intestinal organoid culture			
Project Overview: The research team plans to culture intestinal organoid in vitro derived from the rodent strains in house, including WKY, SHR, Dahl S, and Dahl R rats. They will take intestines from euthanized rats (strains listed above). Gut microbiota-derived metabolites will be used to treat the intestinal organoids. Treated organoids will be collected for gene and protein expression analysis.			
NIH Guideline Section Not applicable. Recombinant and Synthetic DNA are not involved			
Risk Assessment and Discussion Types of biological hazards associated with this protocol are as follows, • Rat tissue. Potential sources of risk are through aerosol inhalation and sharps injuries. The committee discussed the proposed precautions outlined in the protocol such as PPE requirements, waste disposal procedures, handling of aerosol generating equipment, safe handling and disposal of sharps and determined that the proposed precautions are appropriate and sufficient.			
Occupational Health Representative review (if applicable): • Provide clarification for the Biosafety level and Risk group level.			
IBC vote: A member made a motion for Modifications required for approval, then Designated			

Member Review (Chair, Primary and Secondary reviewers). Another member seconded. The required modifications were:

1. Add more information to the objectives section in particular please specify whether you obtain these cells from live animals or provided to you by another researcher. If taking from a live animal, please change the answer in Section C.5 to yes.
2. Clarify what will be done with these organoids
3. Add any imaging systems you plan to use to follow the organoid development. Depending on the microscope used, this may require an SOP for live cells if using a core facility.

Total Votes: 9, For: 9, Against: 0, Abstain: 0

IBC #108664-Renewal	**P.I.:** Dr. Dayanidhi Raman	**Training:** IBC Biosafety Training and IBC Laboratory Safety Training	**Biosafety Level Assignment:** BSL-2

Title: Role of eIF4A1 pathway in breast cancer

Project Overview:

The long term objective of this study is to investigate the key role of eIF4A1 pathway in promoting primary tumor progression and metastasis in breast cancer. Metastasis is the primary cause of mortality in breast cancer.

Currently, the research team is studying the impact of eIF4A1 pathway in the translation of oncogenic mRNAs. The resultant oncogenic translatome would facilitate primary tumor progression, local invasion and metastasis of the breast cancer cells

This will be studied by employing human breast cancer and mouse mammary carcinoma cell lines, breast cancer tissue microarrays, human biospecimens (from CHTN, Ohio State Univ.) and immunocompromised and immunocompetent murine models.

NIH Guideline Section

Section II-A-1, Section II-A-3, Appendix G-II-B-1a to 1h, G-II-B-2a to 2m, Appendix G-II-B-3a, 3a1 and 3a2, Appendix G-II-B-4a to 4f, Appendix G-III-N

Risk Assessment and Discussion

Types of biological hazards associated with this protocol are as follows:

- Lentivirus - 2nd generation system involving psPAX2 and pMD2.G packaging plasmids

- Bacteria - BL21 (for protein expression), DH5-alpha (for plasmid cloning), Stbl2
- Human breast cancer cell lines
- Inflammatory breast cancer (IBC) cell lines
- Human embryonic kidney cells
- Mouse mammary carcinoma cell lines

Potential sources of risk are through aerosol inhalation, needle stick and sharps injuries, and skin contamination. The committee discussed the proposed precautions outlined in the protocol such as PPE requirements, waste disposal procedures, handling of aerosol generating equipment, safe handling and disposal of sharps, and determined that the proposed precautions are appropriate and sufficient.

Occupational Health Representative review (if applicable):

- N/A

IBC vote:

A member made a motion for 'Modifications required for approval, then Designated Member Review (Chair only). Another member seconded. The required modifications were:

1. Please update the FACS SOP to include the new FACSDiscover S8 and personnel.
2. Please add the FACS Core Facility and DLAR for IVIS imaging for locations
3. Please remove BSL2+ or BSL3 unless you really intend to use them
4. The cell lines should be included in the biohazard section and should be removed from the infectious material section
5. Add lentivirus to infectious material section

Total Votes: 9, For: 9, Against: 0, Abstain: 0

IBC #500065-Renewal	**P.I.:** Dr. James Burkett	**Training:** IBC Biosafety Training and IBC Laboratory Safety Training	**Biosafety Level Assignment:** BSL-2

Title: Viral vectors for transfection into mouse and prairie vole

Project Overview:

The goal of the research projects associated with this IBC protocol is to transfect living animals (mouse and prairie vole) with viral vectors containing recombinant DNA plasmids. These plasmids contain genes or other artificial genetic sequences that are intended to express proteins in the live animal that modify neuronal function in the brain, in order to advance the research goals of the associated IACUC protocols. The genes

contained in these plasmids are not oncogenic, toxic, or otherwise harmful to the animal or the environment. These viral vectors will be ordered from external sources, received, prepared into sterile injection solutions, stored at -80 Celsius, and injected into the brains of live animals during stereotaxic surgery. There are no plans to replicate viruses within the lab or to use viruses with cell lines at this time.

NIH Guideline Section

Appendix B-I, Section III-D-4-a

Risk Assessment and Discussion

Types of biological hazards associated with this protocol are as follows,

- All viruses on this protocol are replication-incompetent and do not encode for oncogenes or toxins. Based on the AAV guidance document from the IBC, these are all considered BSL-1
- Blood/tissue from rodents

Potential sources of risk are through aerosol inhalation, needle stick and sharps injuries, and skin contamination. The committee discussed the proposed precautions outlined in the protocol such as PPE requirements, waste disposal procedures, handling of aerosol generating equipment, safe handling and disposal of sharps, and determined that the proposed precautions are appropriate and sufficient.

Occupational Health Representative review (if applicable):

- Delete DLAR room numbers.

IBC vote:

A member made a motion for 'Modifications required for approval, then Designated Member Review (Chair only). Another member seconded. The required modifications were:

1. Please add behavior core to the list of locations
2. P1 bacteriophage is not an eukaryote and neither is Halobacterium. Please remove those organisms incorrectly listed as eukaryotes.
3. SOP is missing information on the nature of the BSL1 agent and the PI's lab room number.

Total Votes: 9, For: 9, Against: 0, Abstain: 0

New Business/Additional Topics: none

Review of incidents: none

Inspections/Ongoing oversight: none

IBC training for members: none

Public comments: none

Adjournment: The IBC Chair moved to adjourn the meeting at 1.06 PM. The next meeting scheduled is for January 15th at 12.00 PM via MS Teams and in-person (HEB 233).